Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)
Clinical trial NCT05856695 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05856695
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-17
- Primary completion
- 2026-11-01
- Enrollment
- 67
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.